Cite
HARVARD Citation
Datta, J. et al. (2015). Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast cancer research. 17 (1), pp. 1-15. [Online].